SSSD 2023

/ SSSD2023/

57th Annual Meeting of the Scandinavian Society for the Study of Diabetes (SSSD2023) in Aarhus

The registration for the 57th Annual Meeting of the Scandinavian Society for the Study of Diabetes (SSSD2023) in Aarhus, Denmark is now open https://ddeacademy.dk/events/57th-annual-meeting-scandinavian-society-study-diabetes-sssd2023. The Annual Meeting will be held 24-26 May 2023 at the new Steno Diabetes Center Aarhus.

We encourage all researchers/clinicians working within any field of diabetes to participate. Participants are encouraged to submit abstracts, and participation is guaranteed for all who have submitted an abstract. All accepted abstracts will be presented orally with two Outstanding Presentation Awards each of 5000 NOK awarded to the two best presentations.

The program will alternate between invited talks within different areas of diabetes research (complications, epidemiology, appetite regulation, adipose tissue, glucagon, lifestyle interventions), and short oral presentations from participants.

Priority will be given to networking and social events, which will be incorporated throughout the meeting, to facilitate and strengthen collaborative relationships. During the meeting, the annual SSSD research prizes are awarded with presentations from the prize recipients (Knud Lundbæk Award, SSSD Young Investigator Award, Novo Nordisk Foundation Lecture Prize and The Swedish Child Diabetes Foundation Nordic Prize).

Public Defence January 19: Archana Sharma

/

Cand.med. Archana Sharma at Institute of Clinical Medicine will be defending the thesis “Glucose metabolism in South Asian and Nordic women with previous gestational diabetes mellitus” for the degree of PhD (Philosophiae Doctor).

Time and place: Jan. 19, 2023 12:15 PM, Store auditorium (Frontbygget), Akershus Universitetssykehus, Sykehusveien 25, Lørenskog

For more information, click Public Defence: Archana Sharma - Institute of Clinical Medicine (uio.no)

Important novel data from the EPIPREG study presented in the prestigious journal Diabetes

/

With data from the EPIPREG sample, we identified six cross-ancestry CpG sites related to insulin resistance in pregnancy, whereof five were replicated in independent studies. From methylation quantitative trait loci analysis, we identified gene variants related to all five replicated cross-ancestry CpG sites, which were associated with several cardiometabolic phenotypes. Mediation analyses suggested that the gene variants regulate insulin resistance through DNA methylation.

DIABETES, December 19th 2022, online ahead of print: Click here

Lifetime risk, life expectancy, and years of life lost to type 2 diabetes in 23 high-income jurisdictions: a multinational, population-based study

/

Using data from 24 population-based data sources from Europe, Asia, North America, and Oceania, we estimated the lifetime risk of type 2 diabetes, life expectancy in people with and without type 2 diabetes, and years of life lost to type 2 diabetes. With the incidence of type 2 diabetes declining in the high-income setting, there has been a corresponding decrease in lifetime risk in many high-income jurisdictions.

However, the burden of diabetes remains high. This substantial individual burden should be considered in future public health strategy and emphasised in patient counselling to improve health outcomes for people with type 2 diabetes.

THE LANCET Diabetes and Endocrinology VOLUME 10, ISSUE 11, NOVEMBER 01, 2022

Sindre Lee Ødegård (post-doc) får stipend fra Norsk endokrinologisk Forening

/

Astra-Zeneca og Norsk Endokrinologisk Forening har lyst ut forskningsmidler ment for å stimulere klinisk forskning i Norge innen terapiområdet diabetes.

Post-doc Sindre Lee-Ødegård ved UiO har søkt om midler for å gjennomføre proteom-kartlegging hos 60 personer med risiko for type 2 diabetes (kvinner av sør-asiatisk eller nordisk opprinnelse med tidligere svangerskapsdiabetes) med mål om å forbedre patofysiologisk forståelse, risiko-stratifisering og identifikasjon av mulige nye behandlingsmål/intervensjonsmuligheter. Prosjektet fremstår å være gjennomførbart, hvor søker kommer fra et faglig sterkt miljø og har en solid publikasjonsliste.

Tematisk tilhører prosjektet et spennende felt innen presisjonsmedisin, med potensiale for nye funn som på sikt kan ha klinisk nytte.

Live enteroviruses, but not other viruses, detected in human pancreas at the onset of type 1 diabetes in the DiViD study

/

The team behind the DiViD study previously reported the presence of enterovirus (EV) genome and proteins in pancreatic sections from six live newly diagnosed patients with type 1 diabetes. In this issue, Krogvold et al (https://doi.org/10.1007/s00125-022-05779-2) confirm the presence of EVs and also demonstrate that no other common human viruses are present in the pancreases of the six DiViD cases.

The authors demonstrate that the EV strains detected represent live infectious viruses capable of establishing a persistent pancreatic infection. As previously shown in persistent EV infection of the heart, persistent EV infection of the pancreas could lead to progressive tissue-specific dysfunction. The authors conclude that the early phase of type 1 diabetes is associated with low-grade EV infection. They go on to suggest that the findings strengthen the need for studies exploring the potential benefits of enteroviral vaccines for individuals at high risk of developing type 1 diabetes and antiviral treatment for individuals in the early phase of type 1 diabetes

World diabetes day: estimating the global incidence of type 1 diabetes among children and adolescents

/

A new study was published in Lancet Diabetes & Endocrinology this week, estimating that around 200 000 new cases of type 1 diabetes was diagnosed in the year 2021, and a substantial number of additional cases occurred that were not diagnosed (1). Lars C. Stene at NIPH and Oslo Diabetes Research Centre, and Aveni Haynes from The University of Western Australia, Perth commented on this new study and another recent study (2) combining available data and simulation, highlighting some of the main findings as well as weaknesses and outstanding questions (3).

In addition to the increasing incidence in the coming decades, it is clear that incidence data are lacking from a large fraction of the most populous countries of the world, and that many children and adolescents die every year without properly being diagnosed and treated for type 1 diabetes.

References

1.  Ward ZJ, Yeh JM, Reddy CL, Gomber A, Ross C, Rittiphairoj T, et al. Estimating the total incidence of type 1 diabetes in children and adolescents aged 0 -19 years from 1990 to 2050: a global simulation-based analysis. Lancet Diabetes Endocrinol 2022 (published online November 2022 https://doi.org/10.1016/S2213-8587(22)00276-5).

2.  Gregory GA, Robinson TIG, Linklater SE, Wang F, Colagiuri S, de Beaufort C, et al. Global incidence, prevalence, and mortality of type 1 diabetes in 2021 with projection to 2040: a modelling study. Lancet Diabetes Endocrinol. 2022;10(10):741-60.

3. Stene LC, Haynes A. Trending now: modelling global epidemiology of type 1 diabetes in children and adolescents. Lancet Diabetes Endocrinol 2022 (published online, November 2022 https://doi.org/10.1016/S2213-8587(22)00306-0, Commentary).

Relation of Health-Related Quality of Life with Glycemic Control and Use of Diabetes Technology in Children and Adolescents with Type 1 Diabetes: Results from a National Population Based Study

/

Lower HbA1c measurements and male sex were associated with higher health-related quality of life (HRQOL) in the age group 10-17 years, but not in children under 10 years. Insulin pump and CGM use were not significantly associated with HRQOL.

Heiko Bratke, Eva Biringer, Hanna D. Margeirsdottir, Pål R. Njølstad, and Torild Skrivarhaug

Journal of Diabetes Research, Volume 2022 | Article ID 8401328 | https://doi.org/10.1155/2022/8401328

NEW International Study: Impact of COVID-19 on long-term trends

/

Impact of the COVID-19 pandemic on long-term trends in the prevalence of diabetic ketoacidosis at diagnosis of paediatric type 1 diabetes: an international multicentre study based on data from 13 national diabetes registries

Niels H Birkebaek*, Clemens Kamrath*, Julia M Grimsmann, Karin Aakesson, Valentino Cherubini, Klemen Dovc, Carine de Beaufort, Guy T Alonso, John W Gregory, Mary White, Torild Skrivarhaug, Zdenek Sumnik, Craig Jefferies, Thomas Hörtenhuber, Aveni Haynes, Martin De Bock, Jannet Svensson, Justin T Warner, Osman Gani, Rosaria Gesuita, Riccardo Schiaffini, Ragnar Hanas, Arleta Rewers, Alexander J Eckert, Reinhard W Holl, Ondrej Cinek

Published: October 03, 2022 DOI:https://doi.org/10.1016/S2213-8587(22)00246-7

Public Defence: Mette Eskild Bornstedt, December 12th 2022

/

Cand.med. Mette Eskild Bornstedt at Institute of Clinical Medicine will be defending the thesis “The effect of vitamin D metabolites on glucose-stimulated insulin secretion (GSIS) and gene expression in murine insulin producing β-cells and pancreatic islets – an experimental study” for the degree of PhD (Philosophiae Doctor).

Time and place: Dec. 12, 2022 1:15 PM, Rødt auditorium i Laboratoriebygget (25), Ullevål universitetssykehus, Kirkeveien 166

For more information, click here

End-stage renal disease: incidence and prediction by coronary heart disease, and educational level. Follow-up from diagnosis of childhood-onset type 1 diabetes throughout Norway 1973–2017.

/

Available online: April 6, 2022

Saeed M, Stene LC, Reisæter AV, Jenssen TG, Tell GS, Tapia G, Joner G, Skrivarhaug T. Annals of Epidemology: https://doi.org/10.1016/j.annepidem.2022.03.015

Purpose: To investigate incidence of end-stage renal disease (ESRD), and the association of education and coronary heart disease (CHD) with ESRD, in subjects throughout Norway followed from the diagnosis of childhood-onset type 1 diabetes.

Mortality trends in type 1 diabetes: a multicountry analysis of six population-based cohorts

/

Paz L. D. Ruiz, Lei Chen, Jedidiah I. Morton, Agus Salim, Bendix Carstensen, Edward W. Gregg, Meda E. Pavkov, Manel Mata-Cases, Didac Mauricio, Gregory A. Nichols, Santa Pildava, Stephanie H. Read, Sarah H. Wild, Jonathan E. Shaw & Dianna J. Magliano Diabetologia (2022)

People with type 1 diabetes have a higher risk of mortality than do people without diabetes, but it is unclear how the excess risk of death in people with type 1 diabetes has changed over time.

In this study we assembled aggregate data on mortality during the period 2000–2016 in people with type 1 diabetes aged 0–79 years from Australia, Denmark, Latvia, Scotland, Spain (Catalonia) and the USA (Kaiser Permanente). We found an all-cause mortality rates in people with type 1 diabetes in the six data sources from 2000 to 2016. The excess mortality in people with type 1 diabetes relative to those without diabetes, declined over time in half of the six included data sources. People with type 1 diabetes still had a 2–5 times higher risk of death compared to those without diabetes Continuous improvement in the multidimensional management for people with type 1 diabetes is critical for on-going reductions in mortality.

How Long-Term Physical Activity May Reduce Insulin Resistance

/

Insulin resistance is a core finding in patients with type 2 diabetes mellitus (T2DM) and physical activity has the potential of improving insulin resistance. In a newly published review, Sindre Lee Ødegaard and co-workers describe a model of potential mechanisms behind the beneficial effects of physical activity on insulin resistance. They briefly summarize an integrated physiological perspective on insulin resistance and describe the effects of long-term PA on signaling molecules involved in cellular responses.

https://www.mdpi.com/2218-1989/12/3/208